# PureTech Health Spins Out Celea Therapeutics with Financing to Launch Phase 3 IPF Trial

> financing · REPORTED · 2026-07-01

Celea Therapeutics launched as an independent company from PureTech Health with financing from RA Capital Management, Leaps by Bayer, and a sovereign wealth fund, with proceeds funding the SURPASS-IPF head-to-head Phase 3 trial evaluating deupirfenidone against pirfenidone in idiopathic pulmonary fibrosis, with trial initiation planned for early Q3 2026.

About Celea Therapeutics: Celea Therapeutics is a Boston-based clinical-stage biopharmaceutical company spun out of PureTech Health that is developing deupirfenidone, a next-generation antifibrotic, for the treatment of idiopathic pulmonary fibrosis.

- Company: Celea Therapeutics
- Sector: therapeutics
- Primary source: https://www.biobucks.co/biotech-vc-funding-tracker-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.